32results about How to "Improve movement disorders" patented technology

Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Disclosed herein are methods and compositions that can be used to treat and diagnose parkinsonism, for example Parkinson's disease, and uses for the same.

The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and / or a COMT inhibitor and / or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and / or a COMT inhibitor, and / or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

The invention discloses an application of a PDE (phosphodiesterase)4 inhibitor. The PDE4 inhibitor is FCPR16, and the structural formula of the inhibitor is represented in the description; FCPR16 is applied to preparation of drugs for preventing or treating PD (Parkinson's disease) or applied to preparation of drugs for repairing dopaminergic neuron damage. The application of the inhibitor in preparation of drugs for treating PD is disclosed for the first time, the new application field of the PDE4D inhibitor FCPR16 is expanded, and the inhibitor has good effect on dyskinesia of PD; the inhibitor can repair retrogression, apoptosis or oxidative damage of dopaminergic neurons.

The invention provides a medicine for treating Parkinson's disease, which is prepared from prepared rhizome of rehmannia, pulp of dogwood fruit, red ginseng, raw astragalus root, root of red rooted saliva, leeches, silkworm, and scorpion.

The invention provides new application of indole-3-carbinol (I3C), diindolyl methane (DIM) and derivative compounds thereof in preparation of medicaments for treating senile dementia. By improving the expression of intracellular free radical resistant specific genes, the medicaments can enhance the automatic free radical clearing capacity of cells and lighten the harm of free radicals to the cells and tissues. The DIM, the I3C and the derivative compounds can effectively reduce the pathogenetic symptoms of senile dementia animal models, obviously improve the dyskinesia of SAM-P / 8 mice, obviously improve the superoxide dismutase (SOD) activity of brain tissues of the SAM-P / 8 mice, reduce the methylene dioxyamphetamine (MDA) content of brain tissues, reduce the choline esterase activity of the brain tissues and enhance the activities of Na<+>-K<+>-ATP enzyme and Ca<2+>-ATP enzyme of the brain tissues, so the DIM, the I3C and the derivative compounds can be used as candidate medicament molecules for treating the senile dementia. Meanwhile, the adopted small molecular substances are easily obtained, are low in price, stable in properties and convenient for storage and transportation, and have broad application prospect.

The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and / or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

The invention provides application of a saffron pigment composition in the preparation of medicines for treating Parkinson's disease, and relates to the field of medicines. Found in study, the saffronpigment composition extracted from plants has the advantages that the mobility dysfunction of a mouse can be obviously relieved, the number of TH (tyrosine hydroxylase) positive neurons in substantianigra is increased, the content of DA (dopamine) in the brain striatum of the mouse is increased, and the certain dose reliance is realized; the obvious treatment function is realized on the Parkinson's disease model mouse caused by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), and the certain anti-Parkinson's disease activity is realized.

The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and / or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and / or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and / or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

Provided is a rehabilitation support device for supporting rehabilitation of a user having impaired mobility, configured to effectively improve the user's mobility by supporting the rehabilitation. This rehabilitation support device is provided with: a request unit for requesting a target movement to be performed in a three-dimensional space; and a feedback unit for sending, approximately simultaneously with the completion of the target movement, feedback that stimulates at least two of five senses, the feedback being sent to the user who has performed the target movement.

The invention relates to the field of gene engineering, in particular to a target protein of Parkinson's disease (PD) and an encoding gene and application thereof, and particularly relates to preparation of a gene targeting drug aiming at the key gene. The target protein finds that a target gene ZIP13 and Transferrin (Tsf) for Parkinson's disease are provided, and the PD condition is remarkably relieved or delayed by over-expressing the ZIP13 or interfering the Tsf through gene silencing. According to the target protein the human PD target protein comprises amino acid sequences represented bySEQ ID No. 5 and SEQ ID No. 6, and the gene comprises nucleotide sequences represented by SEQ ID No. 7 and SEQ ID No. 8. According to the target gene, an RNAi vector carrying a target gene is constructed, and the athletic ability of a PD patient can be improved through gene silencing or gene overexpression, and PD symptoms caused by knockdown of PINK1 is relieved or prevented. The target protein is expected to provide a novel treatment strategy and a key target for treating hereditary PD.

The invention discloses a method for avoiding a moving obstacle in a UUV navigation process based on virtual puffing, and relates to the method for avoiding the moving obstacle in the UUV navigation process. The invention aims at solving a problem that a conventional moving obstacle avoiding method is difficult to predict the moving state of a random moving obstacle accurately. The method comprises the steps: firstly determining that an UUV and the moving obstacle navigate in opposite directions or in the same direction, adjusting the heading of the UUV through employing a puffing and rectangular virtual obstacle when the UUV and the moving obstacle navigate in opposite directions, and avoiding the moving obstacle, wherein the navigation in the same direction comprises two types: the UUV follows the moving obstacle and the moving obstacle follows the UUV; adjusting the heading of the UUV through employing the puffing and rectangular virtual obstacle when the UUV follows the moving obstacle, and avoiding the moving obstacle; enabling the UUV to continuously adjust the moving speed when the moving obstacle follows the UUV, adjusting the heading of the UUV through employing the puffing and rectangular virtual obstacle, and avoiding the moving obstacle. The method is used in the field of moving obstacle avoiding of UUVs.

The invention discloses a small molecule polypeptide TAT‑PSYN and its application in the preparation of drugs for preventing or treating Parkinson's syndrome. By synthesizing the fusion protein TAT-pSyn of the TAT protein transduction domain and the protein polypeptide that can bind to and inhibit the synuclein (alpha-synuclein), the pSyn protein polypeptide is transported through the blood through the blood-brain barrier by TAT, and is neuron Yuan uptake. Applying the polypeptide to the Alpha‑synuclein (A53T) transgenic mouse model of Parkinson’s disease can effectively block the combination of synuclein (alpha‑synuclein) and death-associated protein kinase 1 (DAPK1), and inhibit the α‑synuclein (alpha‑synuclein) The loss of dopamine neurons and nerve projections caused by synuclein phosphorylation and abnormal aggregation can reduce the dyskinesia of Parkinson's model, and provide molecular targets for clinical treatment of Parkinson's syndrome drugs.

The present invention relates to the field of genetic engineering, in particular, the present invention relates to a target protein of Parkinson's Disease (PD) and its encoding gene and application, and particularly relates to the preparation of gene-targeted drugs for the above-mentioned key genes. The present invention provides the target genes ZIP13 and Transferrin (Tsf) of Parkinson's disease, and significantly alleviates or delays PD by overexpressing ZIP13 or interfering with Tsf by gene silencing. According to the present invention, the target protein of human PD includes the amino acid sequences shown in SEQ ID No. 5 and SEQ ID No. 6, and the gene includes the nucleus as shown in SEQ ID No. 7 and SEQ ID No. 8. nucleotide sequence. According to the target gene of the present invention, constructing an RNAi vector carrying the target gene can be used to improve the exercise ability of PD patients through gene silencing or gene overexpression, and slow down or prevent PD symptoms caused by knockdown of PINK1. This invention is expected to provide new therapeutic strategies and key targets for the treatment of hereditary PD.